Generic Motpoly XR Availability

Last updated on Jun 11, 2025.

Motpoly XR is a brand name of lacosamide, approved by the FDA in the following formulation(s):

MOTPOLY XR (lacosamide - capsule, extended release;oral)

• Manufacturer: AUCTA
  Approval date: May 4, 2023
  Strength(s): 100MG ^[RLD], 150MG ^[RLD], 200MG ^[RLD]

Is there a generic version of Motpoly XR available?

No. There is currently no therapeutically equivalent version of Motpoly XR available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Motpoly XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Lacosamide pharmaceutical composition and dosage form thereof
  Patent 11,337,943
  Issued: May 24, 2022
  Inventor(s): Lyu; Shaoqiong et al.
  Assignee(s): SHANGHAI AUCTA PHARMACEUTICALS CO., LTD. (Shanghai, CN)
  

  A dosage form of lacosamide and a pharmaceutical dosage form thereof is disclosed. The dosage form includes an extended release portion and optionally an immediate release portion. Also provided are methods of providing extended release of lacosamide and treatment of a neurological or psychiatric disease or condition.

  Patent expiration dates:

  • June 5, 2040
    
    ✓ 
    Patent use: TREATMENT OF PARTIAL-ONSET SEIZURES IN ADULTS AND IN PEDIATRIC PATIENTS WEIGHING AT LEAST 50 KG
    ✓ 
    Drug product
  • June 5, 2040
    
    ✓ 
    Patent use: ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND IN PEDIATRIC PATIENTS WEIGHING AT LEAST 50 KG
    ✓ 
    Drug product
• Lacosamide pharmaceutical composition and dosage form thereof
  Patent 11,883,374
  Issued: January 30, 2024
  Inventor(s): Lyu; Shaoqiong et al.
  Assignee(s): SHANGHAI AUCTA PHARMACEUTICALS CO., LTD. (Shanghai, CN)
  

  A dosage form of lacosamide and a pharmaceutical dosage form thereof is disclosed. The dosage form includes an extended release portion and optionally an immediate release portion. Also provided are methods of providing extended release of lacosamide and treatment of a neurological or psychiatric disease or condition.

  Patent expiration dates:

  • June 5, 2040
    
    ✓ 
    Patent use: TREATMENT OF PARTIAL-ONSET SEIZURES IN ADULTS AND IN PEDIATRIC PATIENTS WEIGHING AT LEAST 50 KG
    ✓ 
    Drug product
  • June 5, 2040
    
    ✓ 
    Patent use: ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND IN PEDIATRIC PATIENTS WEIGHING AT LEAST 50 KG
    ✓ 
    Drug product
• Lacosamide pharmaceutical composition and dosage form thereof
  Patent 12,042,474
  Issued: July 23, 2024
  Inventor(s): Lyu; Shaoqiong et al.
  Assignee(s): SHANGHAI AUCTA PHARMACEUTICALS CO., LTD. (Shanghai, CN)
  

  A dosage form of lacosamide and a pharmaceutical dosage form thereof is disclosed. The dosage form includes an extended release portion and optionally an immediate release portion. Also provided are methods of providing extended release of lacosamide and treatment of a neurological or psychiatric disease or condition.

  Patent expiration dates:

  • June 5, 2040
    
    ✓ 
    Patent use: TREATMENT OF PARTIAL-ONSET SEIZURES IN ADULTS AND IN PEDIATRIC PATIENTS WEIGHING AT LEAST 50 KG
    ✓ 
    Drug product
  • June 5, 2040
    
    ✓ 
    Patent use: ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND IN PEDIATRIC PATIENTS WEIGHING AT LEAST 50 KG
    ✓ 
    Drug product

Related/similar drugs

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer